Myeloproliferative neoplasms Epidemiological Registry inGrowing and Emerging markets - The MERGE Study

ovartis Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Male or female patients >= 18 years of age who have been diagnosed with a Ph-MPN
•according to the 2008 revised World Health Organization criteria
•2.Willing and able to provide written informed consent according to local guidelines prior to
•any study procedures
•3. Have availability of historical medical records that verify diagnosis
•4. Willing to complete and literate in the language of the available health related quality of
•life (HRQoL) instrument either alone or with minimal assistance from caregivers and/or
•trained site personnel

•1. According to the investigatorâ??s opinion, the patient is an unlikely candidate to obtain longterm
•follow-up information for any reasons such as unavailability or severe concomitant
•2. Patients with active alcohol or drug addiction that would interfere with their ability to
•comply with the study requirements
•3. Patients with any concurrent condition that, in the Investigatorâ??s opinion, would
•jeopardize the safety of the patient or compliance with the protocol

发起方

ovartis Healthcare Pvt Ltd